Skip Navigation

Your Environment. Your Health.

Health economics of asthma and rhinitis. II. Assessing the value of interventions

Environmental Health Economic Analysis Annotated Bibliography

Details

Review Cost-effectiveness analysis (CEA)
Authors
Sullivan SD and Weiss KB
Journal
Journal of Allergy and Clinical Immunology
Summary
In this review article, the authors described the elements of comparative economic evaluations for asthma and rhinitis in an attempt to critically evaluate studies from the perspective of one who might use data for decision making. The authors suggested that the quality of economic evidence for asthma and rhinitis is limited, and therefore, the allocation of resources for these diseases will continue to primarily rely on expert opinion rather than evidence-based literature.
Population
Not available

Health Outcomes

  • Reviewed publications that examined — respiratory outcomes (asthma, allergic rhinitis)

Environmental Agents

List of Environmental Agents: (Not available)

Source of Environmental Agents: (Not available)

Economic Evaluation / Methods and Source

Type:

  • Cost-effectiveness analysis (CEA)

Cost Measured:

  • Reviewed publications that assessed costs associated with asthma and rhinitis, including — Healthcare costs (diagnostic testing)
  • education costs (special education, asthma patient education)
  • productive days lost
  • short-stay observation units

Potential Cost Measures: (Not available)

Benefits Measures: (Not available)

Potential Benefits: (Not available)

Location: (Not available)

Models Used: (Not available)

Methods Used:

  • The authors performed a concise review of studies of both asthma and allergic rhinitis that highlight the utility of economic evaluations for clinical and resource decision making.

Sources Used:

  • The cost-effectiveness of budesonide in severe asthmatics aged one to three years (Connett et al., 1993); Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care (O'Byrne et al., 1996); Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily in the treatment of adults and adolescents with asthma (Lundback et al., 2000); additional sources cited in publication

Economic Evaluation / Methods and Source

Citation:

  • Sullivan SD and Weiss KB. 2001. Health economics of asthma and rhinitis. II. Assessing the value of interventions. Journal of Allergy and Clinical Immunology.

Pubmed:

DOI:

NIEHS Funding: (Not available)

Other Funding: (Not available)